Labcorp Holdings Inc. (LH)

Labcorp's stock experienced an all-time high closing price of $289.43 on October 20, 2025. In October 2025, Q3 results showed revenue growth and margin improvement, leading to updated full-year guidance. In February 2026, Q4 results revealed that adjusted EPS beat estimates, but revenue fell slightly short, though an upbeat annual profit forecast for 2026 was provided. The stock initially fell after the Q4 earnings report, but analyst sentiment remained constructive. Labcorp regularly declared quarterly dividends, and there was significant insider selling activity. The stock's weekly volatility has been stable at 4% over the past year.

Labcorp's business relies on sustained demand for its diagnostic testing and biopharma laboratory services, driven by an aging population and increased awareness of preventive healthcare. Q1 is typically a seasonally slower quarter for Labcorp, with diagnostics volume impacted by weather. The company anticipates continued strong performance in its core diagnostics segment for 2026.

Labcorp Holdings, Inc. is a global life sciences company providing laboratory services for diagnosis and healthcare decisions, operating within the healthcare and biotechnology industries. The company is segmented into Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment offers a broad range of clinical laboratory tests, including routine and specialty testing, digital pathology solutions, and online/mobile applications. The Biopharma Laboratory Services segment provides drug development, medical device, and diagnostic development solutions, supporting pharmaceutical, biotechnology, medical device, and diagnostic companies globally.

Labcorp operates one of the largest clinical laboratory networks globally, with operations in approximately 100 countries, primarily in the U.S. It has over 2,000 patient service centers and more than 6,000 in-office phlebotomists in the United States. Globally, Labcorp has more than 75 labs dedicated to research, development, and clinical trial testing, and over 30 U.S. reference and specialty labs for diagnostic testing. Key R&D locations include sites in the U.S., Europe, and Asia-Pacific.

Labcorp's brand reputation received positive recognition as the company was named to the Fortune World's Most Admired Companies™ 2026 List in January 2026, marking its seventh appearance on the list. No specific negative events or controversies significantly impacting Labcorp's brand reputation from official news sources within the last year were found.

Labcorp Holdings is primarily owned by institutional shareholders, who hold 96.94% of the company's shares, while insiders own 1.62%, and retail investors hold 1.45%. The largest institutional shareholder is Vanguard Group Inc., owning 9.85 million shares, representing 11.95% of the company.